Are generic drugs really inferior medicines

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 302-304

  Moore, N ^a   Berdai D ^a   Begaud B ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; WARFARIN;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; ISOMERISM; MAXIMUM PLASMA CONCENTRATION; NOTE; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; SEIZURE;

ANTICONVULSANTS; DRUGS, GENERIC; EPILEPSY; HUMANS; RISK; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 77955866084     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.168     Document Type: Note

References (11)

1. Mattar, M. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int. J. Hematol. 91, 104-106 (2010).
2. FDAnews. FDA considers further regulatory action against McNeil (6 May 2010).
3. Lon, C.T. et al. Counterfeit and substandard antimalarial drugs in Cambodia. Trans. R. Soc. Trop. Med. Hyg. 100, 1019-1024 (2006).
4. Rascati, K.L., Richards, K.M., Johnsrud, M.T. & Mann, T.A. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 29, 769-774 (2009).
5. Rodriguez, C.A., Agudelo, M., Catano, J.C., Zuluaga, A.F. & Vesga, O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J. Infect. 59, 277-280 (2009).
6. Armstrong, T.S., Choi, S., Walker, J. & Gilbert, M.R. Seizure risk in brain tumor patients with conversion to generic levetiracetam. J. Neurooncol. 98, 137-141 (2010).
7. Kesselheim, A.S. et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 300, 2514-2526 (2008).
8. Kesselheim, A.S. et al. Seizure outcomes following the use of generic versus brand-Name antiepileptic drugs: a systematic review and meta-analysis. Drugs 70, 605-621 (2010).
9. Al Wakeel, J.S. et al. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral. Transplant Proc. 40, 2245-2251 (2008).
10. May, S.B. et al. Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil. Braz. J. Med. Biol. Res. 40, 551-555 (2007).
11. Gagne, J.J., Avorn, J., Shrank, W.H. & Schneeweiss, S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin. Pharmacol. Ther. 88, 347-353 (2010).